Alpha Tau Medical Ltd. (DRTS) Stock Analysis — Probabli.AI
AI-powered analysis for DRTS (Alpha Tau Medical Ltd.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $12.64 · Market cap: $1.1B · AI outlook: Bullish
Alpha Tau Medical Ltd. is well-positioned in the biotechnology sector, with promising technology and recent regulatory advancements boosting its outlook. While financial performance raises some concerns, the company's strategic partnerships and expanding global presence support a bullish one-year outlook. Clinical success is critical for sustaining long-term growth, and economic uncertainties…
Probabilistic 1-Year Outlook
- Bull 45% · Neutral 35% · Bear 20%
- 1-year price estimates — P10: $10 / P50: $14 / P90: $18
- Alpha Tau Medical, with recent positive regulatory approvals and successful clinical trial results, is poised for growth. Despite EPS misses and short-seller attacks, the analyst consensus remains a BUY, indicating…
5-Year Outlook
- Bull 50% · Neutral 30% · Bear 20%
- 5-year price estimates — P10: $9 / P50: $18 / P90: $30
SWOT Highlights
- Strength: Innovative cancer treatment technology (Alpha DaRT)
- Strength: Recent regulatory approvals
- Risk: Negative EPS surprises
- Risk: Financial underperformance
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
5 Wall Street analysts rate DRTS a BUY with a mean price target of $12.6.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
DRTS forecast details · DRTS sentiment details
Recent saved forecast research
AI-generated research records, not evaluated investment results.
- Alpha Tau Medical Ltd. (DRTS) — saved
Alpha Tau Medical Ltd. is well-positioned in the biotechnology sector, with promising technology and recent regulatory advancements boosting its outlook. While financial performance raises some concerns, the company's strategic partnerships
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.